Abstract:Palliative care might be beneficial to heart failure. However, the results remain controversial. We conducted a systematic review and meta-analysis to explore the effect of palliative care on heart failure.PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of palliative care versus usual care on heart failure were included. Two investigators independently searched articles, extracted data, and assessed the… Show more
“…Major depression is a common comorbidity in patients with heart failure [30][31][32] and results in poor quality of life, an increased risk for hospitalization, and mortality. [33][34][35][36][37][38][39] A vast majority of heart failure patients have symptoms of depression and anxiety. 3) Depressive symptoms show a strong negative impact on quality of life.…”
Cognitive behavioral therapy has emerged as an important approach to alleviate the depression of patients with heart failure. However, the use of cognitive behavioral therapy for heart failure has not been well established. We conduct a systematic review and meta-analysis to evaluate the efficacy of cognitive behavioral therapy for alleviating depression for heart failure. PubMed, Embase, and the Cochrane Central Register of Controlled Trials are searched. Randomized controlled trials (RCTs) assessing the influence of cognitive behavioral therapy on heart failure are included. Two investigators independently have searched articles, extracted data, and assessed the quality of included studies. Meta-analysis is performed using the random-effect model. Eight RCTs involving 480 patients are included in the meta-analysis. Compared with control intervention for heart failure, cognitive behavioral therapy can substantially decrease depression scale (Std. MD = −0.27; 95% CI = −0.47 to −0.06; P = 0.01), but has no substantial influence on the quality of life (Std. MD = 0.21; 95% CI = −0.01 to 0.42; P = 0.06), self-care scores (Std. MD = 0.12; 95% CI = −0.18 to 0.42; P = 0.44), and 6-minute walk test distance (Std. MD = 0; 95% CI = −0.28 to 0.28; P = 0.99). Cognitive behavioral therapy is associated with significantly decreased depression scale, but with no substantial impact on the quality of life, self-care scores, and 6-minute walk test distance for heart failure.
“…Major depression is a common comorbidity in patients with heart failure [30][31][32] and results in poor quality of life, an increased risk for hospitalization, and mortality. [33][34][35][36][37][38][39] A vast majority of heart failure patients have symptoms of depression and anxiety. 3) Depressive symptoms show a strong negative impact on quality of life.…”
Cognitive behavioral therapy has emerged as an important approach to alleviate the depression of patients with heart failure. However, the use of cognitive behavioral therapy for heart failure has not been well established. We conduct a systematic review and meta-analysis to evaluate the efficacy of cognitive behavioral therapy for alleviating depression for heart failure. PubMed, Embase, and the Cochrane Central Register of Controlled Trials are searched. Randomized controlled trials (RCTs) assessing the influence of cognitive behavioral therapy on heart failure are included. Two investigators independently have searched articles, extracted data, and assessed the quality of included studies. Meta-analysis is performed using the random-effect model. Eight RCTs involving 480 patients are included in the meta-analysis. Compared with control intervention for heart failure, cognitive behavioral therapy can substantially decrease depression scale (Std. MD = −0.27; 95% CI = −0.47 to −0.06; P = 0.01), but has no substantial influence on the quality of life (Std. MD = 0.21; 95% CI = −0.01 to 0.42; P = 0.06), self-care scores (Std. MD = 0.12; 95% CI = −0.18 to 0.42; P = 0.44), and 6-minute walk test distance (Std. MD = 0; 95% CI = −0.28 to 0.28; P = 0.99). Cognitive behavioral therapy is associated with significantly decreased depression scale, but with no substantial impact on the quality of life, self-care scores, and 6-minute walk test distance for heart failure.
“…Advanced HF, also defined as stage D HF, is refractory to medical treatment, especially when patients have coexisting chronic renal failure. [1][2][3][4][5] Under these conditions, extra-and/or intracorporeal renal replacement therapy can improve cardiorenal hemodynamics. It reduces the intravascular volume, corrects acid-base and electrolyte imbalances, and removes uremic toxins, including cytokines.…”
Section: Discussionmentioning
confidence: 99%
“…eart failure (HF) is a progressive disorder whose treatment options are limited and typically ineffective once patients develop end-stage HF. [1][2][3][4] Mortality is especially high when such patients have coexisting chronic renal failure. 5) Under these conditions, extra-and/or intracorporeal renal replacement therapy can improve the cardiorenal hemodynamics.…”
Extra-and/or intracorporeal renal replacement therapy can improve the cardiorenal hemodynamics in patients with advanced heart failure (HF) refractory to medical therapy and renal failure. Here, we report the case of a 51-year-old woman with inotrope-dependent end-stage HF and chronic renal failure due to anthracyclineinduced cardiomyopathy, in whom the induction of hemodiafiltration and subsequent chronic peritoneal dialysis (PD) provided a dramatic improvement of her cardiac hemodynamics from restrictive to almost normal physiology assessed by echocardiography and cardiac catheterization. The patient returned to office work with New York Heart Association functional class I-II symptoms for at least 3 years with continuous ambulatory PD after hospital discharge.
“…Besides the conventional parameters that we selected in this study, various prognostic factors have been reported. [41][42][43] In the next study, we will reselect parameters for the analysis, considering also the multicollinearity.…”
Section: Deterioration Of Dlco In Patients With Stable Chronic Hf-alvmentioning
The diffusing capacity of the lung for carbon monoxide (DLCO) is indicative of the alveolar-capillary membrane function. A reduced DLCO is associated with poor prognosis in chronic heart failure (HF). However, the significance of DLCO as an independent prognostic predictor has not been established. Here, we aimed to determine the prognostic value of DLCO in patients with chronic HF. We enrolled 214 patients (139 females, mean age: 63 ± 16 years, left ventricular ejection fraction [LVEF]: 45 ± 21%) with stable chronic HF who underwent pulmonary function tests. Only never smokers were included in the analysis because smoking can decrease DLCO. During a median follow-up period of 2.1 years, 52 patients (24.3%) experienced cardiac events, including unplanned HF admissions, left ventricular assist device (LVAD) implantations, all-cause deaths, and cardiopulmonary arrests (CPAs). The median percent predicted DLCO (%DLCO) was 87.3%. In a Cox regression analysis, a %DLCO of ! 87.3% was independently associated with the cardiac events, even after adjusting for age, sex, systolic blood pressure (SBP), LVEF, anemia, brain natriuretic peptide, estimated glomerular filtration rate (eGFR), and prior HF admission (hazard ratio [HR]: 1.87, 95% confidence interval: 1.03-3.53, P = 0.030). A reduced DLCO is an independent predictor of poor prognosis in nonsmoking patients with chronic HF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.